[MACC plus thymostimulin (TP-1 Serono) therapy of small cell bronchogenic carcinoma. Clinico-immunologic evaluation of the results of a randomized trial].
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011897:Random Allocation; D013949:Thymus Extracts / Q000008:administration & dosage
D013949:Thymus Extracts; C031407:thymostimulin; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate
Trattamento chemioimmunoterapico MACC più timostimolina (TP-1 Serono) nel carcinoma broncogeno small cell. Valutazione clinico-immunologica dei risultati di un trial randomizzato.